What are some of the new therapies discussed at ASH 2024?
A roundtable discussion on anemia management in
Diagnosis of TP53-mutated myeloid disease by the ICC and WHO fifth edition classifications
Key Points
The ICC and WHO5 differently classify 64% of TP53-mutated disease due to distinct criteria for multihit TP53 mutations and TP53-mutated AML.
ACROBAT interim results support AlloHeme for relapse prediction in AML, MDS
Genome sequencing in the management of myelodysplastic syndromes and related disorders
Abstract
Pediatric Nurse Finds her Way through Aplastic Anemia Treatment
Pediatric nurse to medical student to patient? This was Claire's life. Listen to her story here.
State of the Art Treatment in Myelodysplastic Syndromes
Presenter: Mikkael SekeresProfessor of Medicine, Chief, Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of MedicineMiami, FL, USA
Release Date: December 20, 2024
Congress: ASH 2024
Area: Hematology
Life After MDS and Accomplishing Your Goals
Several years ago, I wrote an emotionally difficult article titled "Will I Reach My Goal?" It was about a book I was writing. The book describes my life and what it was like being hard of hearing in the 60s and 70s without any support in the schools. It covers my experiences within the deaf community and how difficult it was when I lost more hearing from
Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML
Key Points
VEN plus HMA induces superior response rates in patients with R/R AML than conventional salvage therapy.
The VEN plus HMA combination allows for a safe and effective bridging to allo-HCT.